Options
Acetamido-propanoic Acid Derived Compounds as Protease Inhibitors to Target Coronaviruses
File(s)
File | Description | Size | Format | |
---|---|---|---|---|
Coronavirus manuscript draft V2.pdf | 1006.54 KB |
Author(s)
Date Issued
April 2020
Date Available
22T11:52:28Z May 2020
Abstract
Background: Coronavirus infection as evolved into a major pandemic and is currently being treated using established antiviral agents developed for other similar viruses. Considering the frequent mutations rate in this virus, novel drugs will be necessary for effective treatment in future. Hence this study evaluated the potential of acetamido-propanoic acid derived compounds as viral protease inhibitors. Materials and Methods: Using cheminformatics approach novel acetamido-propanoic acid derived compounds were designed and their binding efficacy against the Coronavirus 2019 (Covid-19) protease was tested using Insilco pharmacology. Results: STGYC compounds had physico-chemical features favourable for developing them for potential clinical use. The binding efficacy of STGYC compounds against covid-19 protease was similar to that of favipiravir, which currently being reported to be effective in treating coronavirus infection. Conclusion: STGYC compounds shown favourable features to be further evaluated and developed as viral protease inhibitors.
Sponsorship
University College Dublin
Other Sponsorship
The Royal Society
Stemcology
Type of Material
Journal Article
Publisher
eManuscript Services
Journal
Biology, Engineering, Medicine and Science Reports
Volume
5
Issue
2
Start Page
20
End Page
22
Copyright (Published Version)
2019 Phcog.Net
Language
English
Status of Item
Peer reviewed
ISSN
2454-6895
This item is made available under a Creative Commons License
Owning collection
Views
628
Last Week
1
1
Last Month
4
4
Acquisition Date
Jun 4, 2023
Jun 4, 2023
Downloads
262
Last Week
3
3
Last Month
34
34
Acquisition Date
Jun 4, 2023
Jun 4, 2023